Two members of Congress have introduced a bill that would allow the FDA to approve generic versions of biotechnonology drugs, though it also would allow companies making brand-name biotech drugs to keep their exclusive rights for at least 12 years before the generics could hit the market. It would also require clinical trials for the generics, though the FDA could waive that requirement. Article